We confirmed a similar expression trend at the protein level (Figure 14B), suggesting that IGF2BP3 may be a potential molecular biomarker for the diagnosis and prognosis of glioma, especially GBM, which is expected to be a new therapeutic target for glioma. This evidence concerns the gene IGF2BP3 and glioma.